[go: up one dir, main page]

PT2849760T - Métodos de complexos quelatos de oligonucleótido - Google Patents

Métodos de complexos quelatos de oligonucleótido

Info

Publication number
PT2849760T
PT2849760T PT137915849T PT13791584T PT2849760T PT 2849760 T PT2849760 T PT 2849760T PT 137915849 T PT137915849 T PT 137915849T PT 13791584 T PT13791584 T PT 13791584T PT 2849760 T PT2849760 T PT 2849760T
Authority
PT
Portugal
Prior art keywords
chelate complex
complex methods
oligonucleotide chelate
oligonucleotide
methods
Prior art date
Application number
PT137915849T
Other languages
English (en)
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of PT2849760T publication Critical patent/PT2849760T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
PT137915849T 2012-05-18 2013-05-17 Métodos de complexos quelatos de oligonucleótido PT2849760T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
PT2849760T true PT2849760T (pt) 2020-01-24

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137915849T PT2849760T (pt) 2012-05-18 2013-05-17 Métodos de complexos quelatos de oligonucleótido

Country Status (37)

Country Link
US (1) US9616083B2 (pt)
EP (1) EP2849760B1 (pt)
JP (2) JP6294308B2 (pt)
KR (1) KR101975915B1 (pt)
CN (1) CN104379152B (pt)
AR (1) AR091065A1 (pt)
AU (1) AU2013262415B2 (pt)
BR (1) BR112014028568B1 (pt)
CA (1) CA2873526C (pt)
CL (1) CL2014003135A1 (pt)
CO (1) CO7131388A2 (pt)
CR (1) CR20140522A (pt)
CU (1) CU20140132A7 (pt)
CY (1) CY1122856T1 (pt)
DK (1) DK2849760T3 (pt)
DO (1) DOP2014000263A (pt)
EA (1) EA034799B1 (pt)
EC (1) ECSP14027542A (pt)
ES (1) ES2767333T3 (pt)
HR (1) HRP20200045T1 (pt)
HU (1) HUE047456T2 (pt)
IL (1) IL235402B (pt)
IN (1) IN2014DN08982A (pt)
LT (1) LT2849760T (pt)
MX (1) MX360626B (pt)
MY (1) MY168209A (pt)
NZ (1) NZ701931A (pt)
PH (1) PH12014502484B1 (pt)
PL (1) PL2849760T3 (pt)
PT (1) PT2849760T (pt)
RS (1) RS59914B1 (pt)
SG (1) SG11201407261XA (pt)
SI (1) SI2849760T1 (pt)
SM (1) SMT202000025T1 (pt)
TW (1) TWI648288B (pt)
WO (1) WO2013170385A1 (pt)
ZA (1) ZA201408082B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2203173E (pt) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Resumo
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
JP6270846B2 (ja) 2012-08-30 2018-01-31 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
KR20170029577A (ko) * 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
ES3040945T3 (en) 2015-10-28 2025-11-06 Vertex Pharma Materials and methods for treatment of duchenne muscular dystrophy
JP7412079B2 (ja) * 2015-12-23 2024-01-12 レプルカ プロプライアタリー リミティド 核酸オリゴマーとその用途
KR20230175312A (ko) * 2016-07-05 2023-12-29 바이오마린 테크놀로지스 비.브이. 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506734A (ja) * 1993-04-01 1996-07-23 アイシス・ファーマシューティカルス・インコーポレーテッド ｍＲＮＡキャップ活性に干渉しおよび翻訳を阻害するアンチセンスオリゴ類
US20020166764A1 (en) 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1694959A (zh) * 2002-09-13 2005-11-09 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
AU2003267785C1 (en) * 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006042418A1 (en) 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007036016A1 (en) 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
WO2008017081A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of jnk proteins
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US9107933B2 (en) * 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi

Also Published As

Publication number Publication date
PH12014502484A1 (en) 2015-01-12
CN104379152A (zh) 2015-02-25
AR091065A1 (es) 2014-12-30
TWI648288B (zh) 2019-01-21
DOP2014000263A (es) 2015-01-31
IL235402B (en) 2022-01-01
CU20140132A7 (es) 2015-02-26
CN104379152B (zh) 2018-10-30
BR112014028568B1 (pt) 2022-02-15
US9616083B2 (en) 2017-04-11
CL2014003135A1 (es) 2015-01-09
MX360626B (es) 2018-11-12
MY168209A (en) 2018-10-15
ZA201408082B (en) 2015-12-23
AU2013262415A1 (en) 2014-11-27
HUE047456T2 (hu) 2020-04-28
HK1206259A1 (en) 2016-01-08
AU2013262415B2 (en) 2017-06-22
KR20150016330A (ko) 2015-02-11
JP6294308B2 (ja) 2018-03-14
EP2849760B1 (en) 2019-10-30
CA2873526C (en) 2020-08-18
CO7131388A2 (es) 2014-12-01
MX2014013885A (es) 2015-05-08
DK2849760T3 (da) 2020-02-03
EP2849760A1 (en) 2015-03-25
PL2849760T3 (pl) 2020-05-18
JP2018058853A (ja) 2018-04-12
NZ701931A (en) 2016-06-24
CA2873526A1 (en) 2013-11-21
EA201401276A1 (ru) 2015-04-30
SI2849760T1 (sl) 2020-03-31
SG11201407261XA (en) 2014-12-30
US20130310445A1 (en) 2013-11-21
SMT202000025T1 (it) 2020-03-13
IL235402A0 (en) 2014-12-31
IN2014DN08982A (pt) 2015-05-22
EP2849760A4 (en) 2015-03-25
ES2767333T3 (es) 2020-06-17
ECSP14027542A (es) 2015-12-31
CR20140522A (es) 2014-12-10
HRP20200045T1 (hr) 2020-03-20
EA034799B1 (ru) 2020-03-23
JP2015517503A (ja) 2015-06-22
BR112014028568A2 (pt) 2020-06-02
TW201408689A (zh) 2014-03-01
RS59914B1 (sr) 2020-03-31
LT2849760T (lt) 2020-04-10
CY1122856T1 (el) 2021-05-05
PH12014502484B1 (en) 2021-03-31
KR101975915B1 (ko) 2019-05-08
WO2013170385A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
IL254716B (en) Zinc-lysine conjugate
GB201217018D0 (en) Methods
IL235512A0 (en) New methods
GB201216921D0 (en) Process
GB201207997D0 (en) Process
ZA201408082B (en) Oligonucleotide chelate complex methods
GB201214326D0 (en) Process
GB201213360D0 (en) Process
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
GB2507760B (en) Methods
GB201208874D0 (en) Methods
EP2852660A4 (en) PROCESS
GB201204280D0 (en) Methods
GB201218078D0 (en) Process
GB201209689D0 (en) Methods
GB201216653D0 (en) Process
GB201220686D0 (en) Methods
GB201208756D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201208875D0 (en) Methods
GB201208963D0 (en) Methods
GB201207793D0 (en) Methods
GB201209932D0 (en) Improved process
GB201202052D0 (en) Well cementation